Aurora Cannabis (ACB) Rings Nasdaq Bell Spotlighting Medical-First Global Shift
- Rang the Nasdaq closing bell Feb. 18 to spotlight Aurora’s transition to a medical-first, globally focused cannabis company.
- Highlights operational strengths: multiple consumer and medical brands, controlling Bevo Farms stake, GMP-certified Canadian and German facilities.
- Says medical business drives growth through R&D, patient-focused supply chains and expansion into Canada, Europe, Australia, New Zealand.
Times Square Showcase of Aurora’s Medical-First Shift
Aurora Cannabis is marking a milestone by ringing the Nasdaq closing bell in New York’s Times Square on Feb. 18, using the ceremony to spotlight its transition to a medical-first, globally focused cannabis company. The event, led by CEO and Executive Chairman Miguel Martin alongside a board representative and members of the executive leadership team, is broadcast live from the Nasdaq MarketSite beginning at 3:45 p.m. ET with the bell scheduled for 4:00 p.m. ET. Aurora frames the ceremony as a public signal of progress in scaling operations and capturing higher-margin international markets.
The company is using the occasion to emphasize operational strengths that underpin its medical strategy, including a portfolio of consumer and medical brands — Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.® — and its controlling interest in Bevo Farms Ltd., a leading North American supplier of propagated agricultural plants. Aurora highlights world-class, GMP-certified manufacturing facilities in Canada and Germany as central to delivering consistent, high-quality products for patients and customers across its target markets.
Aurora stresses that its medical business is the clear driver of growth and that continued investment in research and development, global market expansion and a patient-focused supply chain support that trajectory. The company portrays the Nasdaq ceremony as more than a publicity moment, positioning it as reinforcement of strategic focus on scientific expertise, proven performance and patient care while pursuing market access in Canada, Europe, Australia and New Zealand.
Operational Pillars and Market Footprint
Aurora outlines its strategy around scalable manufacturing and proprietary agricultural capabilities, pointing to Bevo Farms and GMP certifications as competitive advantages for supplying regulated medical markets. The company is concentrating on high-margin product lines and regulatory-compliant supply chains to meet patient needs internationally, framing these operational pillars as central to long-term growth.
Public Engagement and Disclosures
Aurora invites stakeholders to watch the live stream on Nasdaq’s MarketSite bell-ringing page and to follow company updates on X and LinkedIn, and directs interested parties to www.auroramj.com for more information. The company also notes that its release contains customary forward-looking statements and that its common shares trade on the Nasdaq and Toronto Stock Exchange under the symbol ACB.
